Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?
Obesity during childhood and adolescence increases susceptibility to multiple sclerosis after accounting for established genetic and environmental risk factors.
Targeting of ECM molecules and their metabolizing enzymes and receptors for the treatment of CNS diseases.
TDP6, a brain-derived neurotrophic factor-based trkB peptide mimetic, promotes oligodendrocyte myelination.
[Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
'The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level - YES'.
Fingolimod does not enhance cerebellar remyelination in the cuprizone model.
The Diagnosis and Treatment of Optic Neuritis.
Simvastatin: Multiple Sclerosis.
Analysis of tremor in multiple sclerosis using Hilbert-Huang Transform.
Dysfunction in Motor Coordination in Neonatal White Matter Injury Model without Apparent Neuron Loss.
Do Flexible Goal Adjustment and Acceptance Help Preserve Quality of Life in Patients with Multiple Sclerosis?
Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cell-Mediated Central Nervous System Autoimmune Disease.
Dopaminergic D2-like agonists produce yawning in the myelin mutant taiep and Sprague-Dawley rats.
Meta-Analysis of the Relationship between Multiple Sclerosis and Migraine.
[Effect of LINGO-1 gene silencing on movement function of EAE mice].
Bone health in patients with multiple sclerosis relapses.
Multiple sclerosis update.
[Anaesthetic management of patient with neurological disease: Focus on regional anaesthesia.]
Increased HLA-E expression in white matter lesions in multiple sclerosis.
Detection of differential protein expression in cerebrospinal fluid of patients with multiple sclerosis through two-dimensional differential in gel electrophoresis.
Subsequent brain tumors in patients with autoimmune disease.
Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis.
Neuropathology of multiple system atrophy: New thoughts about pathogenesis.
Co-existence of tumefactive MS and hepatitis C: A need for further screening and new therapeutic challenge.
Pages
« first
‹ previous
…
476
477
478
479
480
481
482
483
484
…
next ›
last »